IP Library › Granted Patent US 12,226,634
Granted Patent B2
US 12,226,634 · App. 17/330,310 · Granted Feb 18, 2025

High frequency stimulation for treating sensory and/or motor deficits in patients with spinal cord injuries and/or peripheral polyneuropathy, and associated systems and methods

Inventors: Jeyakumar Subbaroyan (Floral Park, NY); Kerry Bradley (Glendale, CA); Dongchul Lee (Agua Dulce, CA)
Assignee: Nevro Corp.
A61N1/36062A61N1/36171A61N1/0551A61N1/36139A61N1/36157A61N1/36175A61N1/37217
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,634
App. No.
17/330,310
Granted
Feb 18, 2025
Kind
B2
Abstract

High frequency stimulation for treating sensory and/or motor deficits in patients with spinal cord injuries and/or peripheral polyneuropathy, and associated systems and methods. A representative method includes addressing the patient's somatosensory dysfunction and/or motor dysfunction, resulting from neuropathy and/or spinal cord injury, by directing an electrical therapy signal to the patient's spinal cord region, the therapy signal having a frequency in a frequency range from 1.5 kHz to 100 KHz.

Claims (30)

1. A method of treating a patient having sensation loss, via spinal cord stimulation, comprising:

in response to the patient having sensation loss, programming a signal generator to deliver a non-paresthesia producing electrical signal having a frequency in a frequency range of 5 kHz to 16 kHz to the patient's spinal cord via at least one implanted signal delivery element,

wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost, and wherein the sensation was lost in association with diabetic neuropathy.

2. The method of claim 1 wherein the signal generator is implantable, the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12, and the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds, and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps.

3. The method of claim 1 wherein the non-paresthesia producing electrical signal has a frequency of 10 KHz.

4. The method of claim 1 wherein the non-paresthesia producing electrical signal has a pulse width in a pulse width range of 10 microseconds to 333 microseconds.

5. The method of claim 1 wherein the non-paresthesia producing electrical signal has a pulse width in a pulse width range of 25 microseconds to 35 microseconds.

6. The method of claim 1 wherein the non-paresthesia producing electrical signal has an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps.

7. The method of claim 1 wherein the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region.

8. The method of claim 7 wherein the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12, inclusive.

9. The method of claim 1 wherein the at least one implanted signal delivery element is positioned in the patient's epidural space.

10. The method of claim 1 wherein the sensation loss is in the patient's foot or leg, and wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost in the patient's foot or leg.

11. The method of claim 1 wherein the non-paresthesia producing electrical signal at least partially alleviates extremity pain associated with the diabetic neuropathy in addition to restoring the sensation.

12. The method of claim 1 wherein the sensation lost in association with the diabetic neuropathy includes sensation loss caused by diabetes.

13. A method of treating a patient having a loss of sensation, via spinal cord stimulation, comprising:

in response to patient having sensation loss associated with diabetic neuropathy, programming a signal generator to deliver, via at least one implanted signal delivery element, a non-paresthesia producing electrical signal having a frequency in a frequency range of 5 kHz to 15 kHz to the patient's spinal cord to at least partially restore the sensation that was lost in association with diabetic neuropathy.

14. The method of claim 13 wherein the signal generator is implantable, the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12, and the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds, and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps.

15. The method of claim 13 wherein the non-paresthesia producing electrical signal has a frequency of 10 KHz.

16. The method of claim 13 wherein the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds, and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps.

17. The method of claim 13 wherein the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 25 microseconds to 35 microseconds, and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps.

18. The method of claim 13 wherein the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12, inclusive.

19. The method of claim 13 wherein the non-paresthesia producing electrical signal at least partially eliminates sensations of tingling, pins-and-needles, and/or electric shock associated with the diabetic neuropathy.

20. The method of claim 13 wherein the sensation loss is in the patient's foot or leg, and wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost in the patient's foot or leg.

21. The method of claim 13 wherein the non-paresthesia producing electrical signal at least partially alleviates extremity pain associated with the diabetic neuropathy in addition to restoring the sensation.

22. The method of claim 13 wherein the sensation lost in association with the diabetic neuropathy includes sensation loss caused by diabetes.

23. A method of treating a patient having sensation loss, via spinal cord stimulation, comprising:

in response to the patient having sensation loss associated with diabetic neuropathy, directing an electrical signal having a frequency in a frequency range of 5 kHz jo 15 khz to the patient's spinal cord region via an implanted signal delivery element,

wherein the electrical signal at least partially restores the sensation that was lost in association with diabetic neuropathy without causing paresthesia in the patient.

24. The method of claim 23 wherein the electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds, and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps.

25. The method of claim 23 wherein the electrical signal at least partially alleviates sensations of tingling, pins-and-needles, and/or electric shock associated with the diabetic neuropathy in addition to restoring the sensation.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2022
From: SUBBAROYAN, JEYAKUMAR; BRADLEY, KERRY; LEE, DONGCHUL
To: NEVRO CORP.
Reel/Frame 060026/0922 →
Continuity (5)
Continuation 16937463 · Jul 23, 2020
Continuation 15874504 · Jan 18, 2018
Provisional Application 62588185 · Nov 17, 2017
Provisional Application 62448320 · Jan 19, 2017
Related Publication 20210275812A1 · Sep 9, 2021
References Cited (147)
US 5806522A · Katims · 1998 [cited by applicant]
US 6721603B2 · Zabara et al. · 2004 [cited by applicant]
US 6871099B1 · Whitehurst et al. · 2005 [cited by applicant]
US 7162304B1 · Bradley · 2007 [cited by applicant]
US 7206632B2 · King · 2007 [cited by applicant]
US 8355797B2 · Caparso · 2013 [cited by applicant]
US 8569935B1 · Kosierkiewicz · 2013 [cited by applicant]
US 8712533B2 · Alataris et al. · 2014 [cited by applicant]
US 8768472B2 · Fang · 2014 [cited by applicant]
US 8903501B2 · Perryman · 2014 [cited by applicant]
US 8918190B2 · Libbus et al. · 2014 [cited by applicant]
US 8954153B2 · Boggs, II · 2015 [cited by applicant]
US 9002477B2 · Burnett · 2015 [cited by applicant]
US 9295841B2 · Fang et al. · 2016 [cited by applicant]
US 9327121B2 · Thacker · 2016 [cited by examiner]
US 9387338B2 · Burnett · 2016 [cited by applicant]
US 9452286B2 · Cowan et al. · 2016 [cited by applicant]
US 9486632B2 · Saab · 2016 [cited by applicant]
US 9486633B2 · Kramer et al. · 2016 [cited by applicant]
US 9533149B2 · Lee et al. · 2017 [cited by applicant]
US 9561371B2 · Elborno · 2017 [cited by applicant]
US 9630011B2 · Lipani · 2017 [cited by applicant]
US 9757584B2 · Burnett et al. · 2017 [cited by applicant]
US 9782589B2 · Oron et al. · 2017 [cited by applicant]
US 9789313B2 · Lipani · 2017 [cited by applicant]
US 9833614B1 · Gliner · 2017 [cited by applicant]
US 9861547B2 · Crunick et al. · 2018 [cited by applicant]
US 9884189B2 · Boggs, II · 2018 [cited by applicant]
US 9895530B2 · Boggs, II · 2018 [cited by applicant]
US 9895539B1 · Heit · 2018 [cited by applicant]
US 9950164B2 · Lipani · 2018 [cited by applicant]
US 10143850B2 · Cowan et al. · 2018 [cited by applicant]
US 10307585B2 · Boggs et al. · 2019 [cited by applicant]
US 10493275B2 · Alataris · 2019 [cited by applicant]
US 10232180B2 · Kramer et al. · 2019 [cited by applicant]
US 10238872B2 · Pivonka et al. · 2019 [cited by applicant]
US 10328256B1 · Gliner · 2019 [cited by applicant]
US 10342977B2 · Raghunathan · 2019 [cited by applicant]
US 10369366B2 · Oron et al. · 2019 [cited by applicant]
US 10426959B2 · Boggs, II · 2019 [cited by applicant]
US 10583284B2 · Peters et al. · 2020 [cited by applicant]
US 10668285B2 · Boggs, II · 2020 [cited by applicant]
US 10799701B2 · Lee · 2020 [cited by applicant]
US 11534611B2 · Baldoni · 2022 [cited by applicant]
US 11986657B2 · Lee et al. · 2024 [cited by applicant]
US 20030018367A1 · DiLorenzo · 2003 [cited by applicant]
US 20030055464A1 · Darvish et al. · 2003 [cited by applicant]
US 20040015204A1 · Whitehurst · 2004 [cited by applicant]
US 20040039425A1 · Greenwood-Van Meerveld · 2004 [cited by applicant]
US 20050240241A1 · Yun et al. · 2005 [cited by applicant]
US 20080033511A1 · Dobak et al. · 2008 [cited by applicant]
US 20080077192A1 · Harry et al. · 2008 [cited by applicant]
US 20090076565A1 · Surwit · 2009 [cited by applicant]
US 20100274314A1 · Alataris · 2010 [cited by applicant]
US 20100274326A1 · Chitre et al. · 2010 [cited by applicant]
US 20120303098A1 · Perryman · 2012 [cited by applicant]
US 20130116754A1 · Sharma et al. · 2013 [cited by applicant]
US 20130204324A1 · Thacker et al. · 2013 [cited by applicant]
US 20130274846A1 · Lad et al. · 2013 [cited by applicant]
US 20140276549A1 · Osorio · 2014 [cited by applicant]
US 20140316484A1 · Edgerton et al. · 2014 [cited by applicant]
US 20150073510A1 · Perryman · 2015 [cited by applicant]
US 20160030408A1 · Levin · 2016 [cited by applicant]
US 20160082252A1 · Hershey et al. · 2016 [cited by applicant]
US 20160121109A1 · Edgerton · 2016 [cited by applicant]
US 20160175594A1 · Min et al. · 2016 [cited by applicant]
US 20160177298A1 · Green · 2016 [cited by applicant]
US 20160213918A1 · Howard et al. · 2016 [cited by applicant]
US 20160256683A1 · Butera et al. · 2016 [cited by applicant]
US 20170036023A1 · Parker · 2017 [cited by applicant]
US 20170095667A1 · Yakovlev · 2017 [cited by applicant]
US 20170274212A1 · Kramer et al. · 2017 [cited by applicant]
US 20170354831A1 · Burnett et al. · 2017 [cited by applicant]
US 20180085580A1 · Perez et al. · 2018 [cited by applicant]
US 20180256906A1 · Pivonka et al. · 2018 [cited by applicant]
US 20180272132A1 · Subbaroyan et al. · 2018 [cited by applicant]
US 20180318585A1 · Pfeifer · 2018 [cited by applicant]
US 20180345020A1 · Ironi et al. · 2018 [cited by applicant]
US 20180361154A1 · Levin · 2018 [cited by applicant]
US 20190001139A1 · Mishra et al. · 2019 [cited by applicant]
US 20190046795A1 · Cakmak · 2019 [cited by applicant]
US 20190151652A1 · Boggs, II · 2019 [cited by applicant]
US 20190232062A1 · Falowski · 2019 [cited by applicant]
US 20190269913A1 · Pivonka et al. · 2019 [cited by applicant]
US 20190321641A1 · Baldoni et al. · 2019 [cited by applicant]
US 20190336776A1 · Cowan et al. · 2019 [cited by applicant]
US 20190351235A1 · Leuthardt et al. · 2019 [cited by applicant]
US 20190374776A1 · Mishra et al. · 2019 [cited by applicant]
US 20200030606A1 · Boggs, II · 2020 [cited by applicant]
US 20200046973A1 · Simon et al. · 2020 [cited by applicant]
US 20200046981A1 · Kramer et al. · 2020 [cited by applicant]
US 20200108251A1 · Raghunathan · 2020 [cited by applicant]
US 20200139138A1 · Sit · 2020 [cited by examiner]
US 20200254255A1 · Lee · 2020 [cited by applicant]
US 20200324113A1 · Fisher · 2020 [cited by examiner]
US 20200353253A1 · Subbaroyan · 2020 [cited by applicant]
US 20210085981A1 · Lee · 2021 [cited by applicant]
US 20210275812A1 · Subbaroyan et al. · 2021 [cited by applicant]
US 20210330981A1 · Mishra et al. · 2021 [cited by applicant]
US 20230248973A1 · Subbaroyan et al. · 2023 [cited by applicant]
JP 2018500143 · 2018 [cited by applicant]
JP 2013521979 · 2021 [cited by applicant]
KR 1020210050493 · 2013 [cited by applicant]
WO WO2013036880 · 2013 [cited by applicant]
WO WO2013116368 · 2013 [cited by applicant]
WO WO2014146082 · 2014 [cited by applicant]
WO WO2017044904 · 2017 [cited by applicant]
WO WO2017142948 · 2017 [cited by applicant]
WO WO2017146658 · 2017 [cited by applicant]
WO WO2018125538 · 2018 [cited by applicant]
WO WO2020051484 · 2020 [cited by applicant]
Seattle Pain Relief. “Seattle Pain Relief Now Helping Diabetic Neuropathy Patients Restore Sensation with Spinal Cord Stimulation. ” PRWeb</i>, Nov. 16, 2015, https://www.prweb.com/releases/diabetic-neuropathy/seattle-t… [cited by examiner]
Al-Kaisy et al., “The Use of 10-Kilohertz Spinal Cord Stimulation in Cohort of Patients with Chronic Neuropathic Limb Pain Refractory to Medical Management,” Neuromodulation: Technology at the Neural Interface, Feb. 201… [cited by applicant]
Tesfaye et al., “Electrical Spinal-Cord Stimulation for Painful Diabetic Peripheral Neuropathy,” The Lancet, vol. 348, Dec. 1996, 4 pages. [cited by applicant]
Van Beek et al., “Spinal Cord Stimulation in Experimental Chronic Painful Diabetic Polyneuropathy: Delayed Effect of High-Frequency Stimulation,” European Journal of Pain, Oct. 2016, 9 pages. [cited by applicant]
Seattle Pain Relief Now Helping Diabetic Neuropathy Patients Restore Sensation with Spinal Cord Stimulation, PRWeb Online Visibility from Vocus, https://www.prweb.com/releases/diabetic-neuopathy/seattle-tacoma-wa/prweb1… [cited by applicant]
Ahmed et al., “Effects of Spinal Cord Stimulation on Pain Thresholds and Sensory Perceptions in Chronic Pain Patients,” Neuromodulation. 2015;18(5):6 pages. [cited by applicant]
Daousi C et al., “Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy” Diabet Med. 2005;22(4):6 pages. [cited by applicant]
De Vos et al., “Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy” Neuromodulation. 2014;17(2): 8 pages. [cited by applicant]
De Vos et al., Effect and safety of spinal cord stimulation for treatment of chronic pain caused by diabetic neuropathy. J Diabetes Complications. 2009;23(1): 6 pages. [cited by applicant]
De Vos et al., “Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial,” Pain. 2014;155(11):.6 pages. [cited by applicant]
Duarte et al., “Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation” Qual Life Res. 2016;25(7):7 pages. [cited by applicant]
Eisenberg et al., “Quantitative Sensory Testing for Spinal Cord Stimulation in Patients With Chronic Neuropathic Pain. Pain Practice” 2006;6(3):5 pages. [cited by applicant]
Eldabe et al. “Retrospective Case Series on the Treatment of Painful Diabetic Peripheral Neuropathy With Dorsal Root Ganglion Stimulation.” Neuromodulation. 2018;21(8): 6 pages. [cited by applicant]
Koetsier et al., “Effectiveness of dorsal root ganglion stimulation and dorsal col. spinal cord stimulation in a model of experimental painful diabetic polyneuropathy,” CNS Neurosci Ther. 2019;25(3): 8 pages. [cited by applicant]
Koetsier et al., “Mechanism of dorsal root ganglion stimulation for pain relief in painful diabetic polyneuropathy is not dependent on GABA release in the dorsal horn of the spinal cord” CNS Neurosci Ther. 2020;26(1): 8… [cited by applicant]
Kumar et al., “Spinal cord stimulation for chronic pain in peripheral neuropathy” Surg Neurol. 1996;46(4):7 pages. [cited by applicant]
Pluijms et al. “Increased contact heat evoked potential stimulation latencies in responders to spinal cord stimulation for painful diabetic polyneuropathy,” Neuromodulation. 2015;18(2) 7 pages. [cited by applicant]
Pluijms et al., “Pain relief and quality-of-life improvement after spinal cord stimulation in painful diabetic polyneuropathy: a pilot study” British Journal of Anaesthesia. 2012;109(4):7 pages. [cited by applicant]
Pluijms et al., “The effect of spinal cord stimulation frequency in experimental painful diabetic polyneuropathy” Eur J Pain. 2013;17(9):9 pages. [cited by applicant]
Slangen et al., “Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial” Diabetes Care. 2014;37(11): 9 pages. [cited by applicant]
Van Beek et al. “Sustained Treatment Effect of Spinal Cord Stimulation in Painful Diabetic Peripheral Neuropathy: 24-Month Follow-up of a Prospective Two-Center Randomized Controlled Trial. Diabetes Care” 2015;38(9):3 p… [cited by applicant]
Van Beek et al., “Long-Term Spinal Cord Stimulation Alleviates Mechanical Hypersensitivity and Increases Peripheral Cutaneous Blood Perfusion in Experimental Painful Diabetic Polyneuropathy” Neuromodulation. 2018;21(5):… [cited by applicant]
Van Beek et al., “Severity of Neuropathy Is Associated With Long-term Spinal Cord Stimulation Outcome in Painful Diabetic Peripheral Neuropathy: Five-Year Follow-up of a Prospective Two-Center Clinical Trial” Diabetes C… [cited by applicant]
Cata et al., “Spinal cord stimulation relieves chemotherapy-induced pain: A Clinical Case Report,” Journal of Pain and Symptom Management-10.1016/j.jpainsymman, vol. 27, No. 1, Jan. 2004, 7 pages. [cited by applicant]
Cision PRWeb, “Seattle Pain Relief Now Offering Groundbreaking Treatments for Diabetic and Peripheral Neuropathy,” http://www.prweb.com/releases/seattle-pain-center/diabeticneuropathydoctor/prweb12492970.htm Jul. 25, 20… [cited by applicant]
Lachance et al., “Stimulation-induced ectopicity and propagation windows in model damaged axons,” J. Comput Neurosci, 2014, 9 pages. [cited by applicant]
McDonnell et al., “Treatment of pain secondary to diabetic peripheral neuropathy (DPN) wit the precisions spinal cord stimulation (SCS) system: a case series,” European Journal of Pain 11(S1), 2007, 1 page. [cited by applicant]
National Institute of Neurological Disorders and Stroke (NINDS), “Paresthesia,” https://www.ninds.gov/Disorders/All-Disorders/Paresthesia-Information-Page#disorders-r3>, 2014. [cited by applicant]
Seattle Pain Relief Video: “What is a Spinal Cord Stimulator,” https://www.painmanagement-seattle.com/spinal-cord-stimulator.html 2016, 5 pages. [cited by applicant]
YouTube Video: Spinal Cord Stimulator Implants Help Diabetic Peripheral Neuropathy (602) 507-6550, https://www.youtube.com/watch?v=EYao-SfPOwo, Jul. 23, 2012, 3 pages. [cited by applicant]
Zhu et al., “Changes in functional properties of A-type but not C-type sensory neurons in vivo in a rat model of peripheral neuropathy,” Journal of Pain Research, Dovepress, 2012, 18 pages. [cited by applicant]
Zhu et al., “Early Demyelination of Primary A-Fibers Induces a Rapid-Onset of Neuropathic Pain in Rat,” Neuroscience 200, 2012, 13 pages. [cited by applicant]
Zhu et al., “Excitability of Aß sensory neurons is altered in an animal model of peripheral neuropathy,” BMC Neuroscience, 13:15, 2012, 15 pages. [cited by applicant]
Mayo Clinic, “Diabetic Neuropathy,” https://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/symptoms-causes/syc-20371580, 1998, 5 pages. [cited by applicant]
Slangen et al., “Sustained effect of spinal cord” stimulation on pain and quality of life in painful diabetic peripheral neuropathy British Journal of Anaesthesla, 2013;111(6):1030-1031, 2 pages. [cited by applicant]
Karamian et al., “The role of electrical stimulation for rehabilitation and regeneration after spinal cord injury,” Journal of Orthopaedics and Traumatology, Jan. 6, 2022, 18 pages. [cited by applicant]
Cited By (1)
US 12,420,098